More on China Cord Blood earnings


China Cord Blood (CO) posts a mixed FQ1, beating on its EPS but missing slightly on top line revenue.

Total sales increased by 11.6% Y/Y, driven by higher storage fees.

Accumulated subscriber base grew to 327,242, +27.7% year-over-year.

Gross margin increased to 81% from 78.9% in the prior year period.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs